Overview

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

Status:
Not yet recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

This study aimed to evaluate the diagnostic performance of 18F-DCFPyL (PyL) PET/CT in subjects presenting not previously treated for castration resistant prostate cancer and showing negative or equivocal findings per institutional standard of care conventional imaging

Phase:

Phase 2

Details

Lead Sponsor:

CHU de Quebec-Universite Laval

Collaborator:

Astellas Pharma Europe Ltd.